Common genetic polymorphisms in pre-microRNAs were associated with increased risk of dilated cardiomyopathy

Bin Zhou1, Li Rao, Ying Peng

  • 1Laboratory of Molecular Translational Medicine, West China Second University Hospital, Sichuan University, Chengdu 610041, PR China.

Abstract

Insights

Common single nucleotide polymorphisms in pre-microRNAs are linked to increased risk of dilated cardiomyopathy (DCM). Specifically, variants in has-mir-196a2 and hsa-mir-499 are associated with higher DCM risk.

Area of Science:

  • Genetics
  • Molecular Biology
  • Cardiology

Background:

  • Single nucleotide polymorphisms (SNPs) in pre-microRNAs can alter microRNA (miRNA) expression and function.
  • These alterations may lead to various functional consequences, potentially impacting disease development.

Purpose of the Study:

  • To investigate the association between common SNPs in pre-microRNAs and the risk of developing dilated cardiomyopathy (DCM).
  • This pilot study aimed to identify specific pre-miRNA SNPs linked to DCM susceptibility.

Main Methods:

  • Genotyping of three pre-miRNA SNPs (has-mir-196a2 rs11614913 C/T, hsa-mir-499 rs3746444 A/G, hsa-mir-146a rs2910164 C/G) was performed.
  • The study included 221 DCM patients and 321 healthy control subjects, with genotyping conducted using PCR-restriction fragment length polymorphism (RFLP) assay.

Main Results:

  • The variant alleles of has-mir-196a2 rs11614913 (T allele) and hsa-mir-499 rs3746444 (G allele) were significantly associated with increased DCM risk (P<0.0001 for both).
  • A dominant model showed a statistically significant association between these two SNPs and increased DCM risk.
  • No significant association was observed between DCM risk and the hsa-mir-146a rs2910164 C/G polymorphism (P=0.451).

Conclusions:

  • The study concludes that common genetic polymorphisms in pre-microRNAs, specifically has-mir-196a2 rs11614913 C/T and hsa-mir-499 rs3746444 A/G, are associated with a significantly increased risk of dilated cardiomyopathy.
  • The hsa-mir-146a rs2910164 C/G polymorphism was not found to be associated with DCM risk in this cohort.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...